The approved product has an estimated market size of US$ 44.5 million for the twelve months ending January 2024
Dr Madhu will oversee Apollo's hospital business and will focus on continuing to deliver the world's best clinical outcomes
To accelerate the development of next-generation radioconjugates to treat cancer
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Additional capacity broadens Grace’s fine chemical capabilities for API production
A five-day inspection was concluded successfully with no critical and no major observations raised
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ II, India
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Subscribe To Our Newsletter & Stay Updated
